Development of lipoprotein-drug conjugates for targeted drug delivery

Abstract

Tumour targeting approaches used in cancer chemotherapy offers prolonged, localized, and protected drug interaction with the diseased tissue with minimal side effects and systemic toxicity, which are accountable for the failure of chemotherapy using conventional delivery systems. The purpose of the present study is to develop an anticancer targeted drug delivery system using synthesized lipoproteins with the integration of quality by design approach. Lipoprotein structures were designed, and quality by design approach was implemented to select variables for optimization. Further, the lipoproteins were synthesized and characterized by physicochemical properties. Physical composites of synthesized lipoproteins with the drug (tablets) were prepared and evaluated for post-compression parameters. Moreover, drug-lipoprotein chemical conjugates were synthesized and characterized for physicochemical properties, including cellular drug uptake and cytotoxicity study on HaCaT cancer cells. Synthesized lipoproteins showed good swelling capacity but poor flowability. Nuclear magnetic resonance and infrared spectroscopy of conjugates showed characteristic peaks. Tablets from all batches extended the drug release up to 12 h. All synthesized conjugates showed improved cellular drug uptake (up to 86.1%) and inhibition (87.39%) of HaCat cancer cells. These findings explored the possible use of synthesized lipoproteins in the development of anti-cancer drug formulation against HaCat cancer cells.

Communicated by Ramaswamy H. Sarma

Keywords:

• Lipoprotein
• drug-lipoprotein conjugate
• targeted drug delivery
• immortalized human HaCaT keratinocyte

Acknowledgements

Authors are thankful to the Principal, Dr. H. N. More, Bharati Vidyapeeth, College of Pharmacy, Kolhapur, Maharashtra, India for providing necessary facilities required to carry out this research work and Dr. Sandip Patil, Adarsh College of Pharmacy, Vita, Maharashtra, India for carring out biological activity

Disclosure statement

The authors declare no competing financial interest.